Can a Low-Dose steroid tame Immunotherapy's liver side effect?
NCT ID NCT07167251
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 32 times
Summary
This study looks at whether low-dose prednisolone can effectively treat liver inflammation (hepatitis) that sometimes occurs as a side effect of immune checkpoint inhibitors in cancer patients. Researchers will enroll 63 adults with grade 2 or 3 immune-related hepatitis and give them prednisolone at 0.5-1 mg per kilogram of body weight. The goal is to see if this low dose resolves the liver problem within 8 weeks without needing stronger medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal Marsden Hospital
NOT_YET_RECRUITINGLondon, SW3 6JJ, United Kingdom
-
University Hospital Basel
RECRUITINGBasel, Canton of Basel-City, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prednisolone (low-dose corticosteroid)
What this could lead to
If successful, this could show that low-dose steroids are enough to control immune-related hepatitis, reducing the need for stronger immunosuppressants.
What could go wrong
This is a small, early-stage registry study with only 63 participants, so results may not apply broadly. The treatment may still fail or require dose escalation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.